ADMA
HealthcareADMA Biologics, Inc.
$18.03
+$0.15 (+0.84%)
Jan 5, 2026
Price History (1Y)
Analysis
ADMA Biologics, Inc. is a biotechnology company operating in the healthcare sector. With a market capitalization of $4.30 billion and revenue of $488.56 million (TTM), it is a significant player in its industry. The company employs 677 individuals. Financially, ADMA Biologics has shown strong profitability, with gross margin at 54.7%, operating margin at 38.0%, and profit margin at 42.9%. Returns on equity and assets are also notable, at 63.2% and 21.8%, respectively. The company's balance sheet indicates $61.38 million in cash and $83.12 million in debt, resulting in a debt to equity ratio of 19.28. ADMA Biologics' valuation metrics include a price-to-earnings ratio (TTM) of 20.72 and forward P/E of 19.18. Revenue growth has been steady at 12.0% year-over-year, while earnings growth has remained flat at 0.0%. The company does not pay dividends.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About ADMA Biologics, Inc.
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Visit website →Key Statistics
- Market Cap
- $4.30B
- P/E Ratio
- 20.72
- 52-Week High
- $25.67
- 52-Week Low
- $13.50
- Avg Volume
- 3.17M
- Beta
- 0.46
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- United States
- Employees
- 677